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The 2016 Albert Lasker Basic Medical Research Award 
honors three physician-scientists: William G. Kaelin, Jr. 
from Harvard Medical School, Peter J. Ratcliffe from Uni-
versity of Oxford and Gregg L. Semenza, from Johns Hop-
kins University School of Medicine, for their discovery of 
the pathway by which cells from human and most animals 
sense and adapt to changes in oxygen availability, a process 
essential for survival. The Lasker Award is widely consid-
ered as America’s most prestigious honor in the biomedical 
field. For 71 years, this award has recognized the contribu-
tions of scientists, clinicians, and public citizens who have 
made exceptional advances in human health problems. 
Kaelin, Ratcliffe and Semenza have revealed the core mo-
lecular events which could explain how cells tune their 
physiology to cope with varying quantities of life-sustaining 
oxygen. These findings might provide novel therapeutics for 
a wide range of disorders such as anemia, cardiovascular 
disease, macular degeneration and cancer. 
HIF-1: THE HYPOXIC GENES 
The journey in the identification and elucidation of mole-
cules critical for oxygen homeostasis started from erythro-
poietin (EPO). Many creatures use red blood cells to carry 
oxygen, which serves as a universal electron acceptor in 
numerous biochemical pathways. When deprived of oxygen, 
the kidney secretes EPO to stimulate the production of new 
blood cells from bone marrow. For years, it remains unclear 
about how cells furnish oxygen supply to control the EPO 
gene. In early 90’s, Semenza and Ratcliffe identified a tran-
scriptional enhancer controlling erythropoietin levels, which 
vary in response to oxygen concentrations. Placement of this 
DNA stretch next to other genes renders those genes induc-
ible by low-oxygen conditions. Protein from the nucleus 
sticks to this DNA-control region, but only when oxygen is 
scarce. Further, sequence alterations that eliminate protein 
binding to the DNA obliterate hypoxia-induced gene stimu-
lation. In 1995, Semenza and Wang purified hypox-
ia-inducible factor 1 (HIF-1) and found that it contains two 
protein partners, HIF-1α and HIF-1β (Wang et al., 1995).  
HIF-1α vanishes quickly when cells are shifted from low- to 
high-oxygen conditions. Under low oxygen conditions, 
HIF-1 binds and activates target genes such as erythropoi-
etin and vascular endothelial growth factor, which plays a 
key role in erythropoiesis and angiogenesis respectively. By 
increasing the new red blood cells and vessels, HIF-1 medi-
ates the adaptive response to hypoxia. In the absence of 
HIF-1α, vascular development and oxygen-dependent gene 
expression are severely impaired, leading to embryonic le-
thality (Iyer et al., 1998). These findings have established 
HIF-1 as the core molecule of an elaborate physiological 
network that ensures advantageous responses to oxygen. 
HIF-1 DRIVEN GENES  
With the discovery of HIF-1 and its binding sequences, 
Ratcliffe, Semenza and other scientists have rapidly ex-
panded the list of hypoxia-induced genes. In addition to 
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EPO and VEGF, HIF-1 binds and activates target genes in 
many mammalian cells broadly involved in the regulation of 
metabolism, angiogenesis, embryonic development, im-
munity and especially cancer. Multiple gene products that 
mediate the metabolic switch are controlled by HIF-1. 
Among these genes are PDK1 gene encoding pyruvate de-
hydrogenase (PDH) kinase I, LDHA gene which encodes 
lactae dehydrogenase, LONP gene encoding a protease that 
degrades COX4-1, acyl CoA dehydrogenase that generates 
AcCoA by oxidation of fatty acids, and BNIP3 and BNIP3L 
which are mitochondrial proteins that trigger mitochondri-
al-selective autophagy. PDK1 phosphorylates and inacti-
vates PDH which converts glucose-derived pyruvate into 
AcCoA for entry into the mitochondrial tricarboxylic acid 
(TCA) cycle. HIF-1 is also essential for hypoxia-induced 
cell cycle arrest which is the fundamental physiological 
response to hypoxia. Over-expression of HIF-1 induces 
G1-phase cell cycle arrest by inhibition of Myc activity and 
its direct interaction with protein components of the 
pre-replication complex. HIF-1 activates cyclin genes that 
cause cancer cells to grow. All these observations have 
suggested that multiple kinds of cells use HIF-1 to alter 
numerous genes in response to low-oxygen conditions.  
VHL-DEPENDENT MODULATION OF HIF-1 
As shown in Figure 1, HIF-1 is stabilized under hypoxic 
conditions, providing long-enough time for it to enter the 
nucleus to stimulate the expression of target genes, which 
promote cells survival in low oxygen conditions. Unearth-
ing how oxygen alters HIF-1 involved one autosomal dom-
inant cancer predisposition syndrome called Von Hip-
pel-Lindau (VHL) disease. VHL disease is characterized by 
tumors of the brain and spine, retina, kidney, adrenal glands, 
and several other organs. The next year after purification of 
HIF, Kaelin, an oncologist who was working on VHLD and 
variants of gene VHL, found that VHL negatively regulates 
HIF via oxygen-dependent proteolysis (Iliopoulos et al., 
1996). VHL protein is a component of a multiprotein com-
plex that bears structural and functional similarity to SCF 
(Skp1/Cdc53 or Cullin/F-box) ubiquitin ligases. Cells lack-
ing functional VHL protein cannot degrade HIF and thus 
overproduce mRNAs encoded by HIF target genes. 
Ratcliffe’s group discovered that VHL protein-deficient 
renal-cancer cells fail to degrade HIF-1α and the other family 
member HIF-2α (Maxwell et al. 1999). The proteosomal 
degradation of HIF-1 occurs through the ubiquitin pathway 
by high-affinity binding to the von Hippel-Lindau E3 ubiq-
uitin ligase. 
Subsequent studies led by Kaelin and Ratliffe have re-
vealed that the enzymes called dioxygenases are critical for 
the recognition of HIF-1 by VHL proteins and its conse-
quent degradation (Ivan et al., 2002; Epstein et al., 2001). 
These enzymes hydroxylate a highly conserved proline res-
idue in HIF-1α. This oxygen dependent HIF-1α prolyl hy-
droxylation governs HIF turnover. In the presence of suffi-
cient oxygen, prolyl hydroxylation promotes HIF-1α deg-
radation. As oxygen levels decline, prolyl hydroxylation is 
rapidly inhibited. An alternative hydroxylation occurs on 
asparagine residues, which blocks the ability of HIF-1α to 
recruit transcriptional coactivators. This dual-safety system 
ensures cells to block any residual HIF-1 escaped from 
degradation (Lando et al., 2002).  
PERSPECTIVES FOR THERAPY 
HIF-1 and its relative molecules regulate a group of genes 
whose products influence a vast variety of biological pro- 
cesses. Manipulating the HIF-1 pathway for therapeutic 
purposes hence offers a great potential. For example, prolyl  
 
 
Figure 1  Oxygen-dependent proteolysis of HIF-1. 
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hydroxylase inhibitors may hold promise for intervention of 
anemia. Results in both animals and humans have shown 
that these inhibitors might preserve HIF-1 and stimulate 
erythropoietin gene activity. Interfering with prolyl hydrox-
ylases might be also effective to counter conditions result-
ing from inadequate circulation by promoting blood-vessel 
growth and other adaptations to hypoxia. On the other hand, 
suppression of HIF-1 provides an alternative approach for 
control of malignancy because of its capability of blocking 
angiogenesis. Indeed, a compound that foils HIF-2α is cur-
rently in early clinical trials for kidney cancer.   
SUMMARY 
As cited by Joseph L. Goldstein, a Nobel Laureate and 
Chair of the Lasker Medical Research Awards Jury, the 
2016 Lasker winners combine exceptional insight, creativi-
ty, and perseverance in pursuing crucial questions in medi-
cal science. This year’s Basic Awardees have deepened our 
understanding of the fundamental pathways by which we 
sense and respond to the presence of oxygen. 
Compliance and ethics  The author(s) declare that they have no conflict 
of interest. 
Epstein, A.C., Gleadle, J.M., McNeill, L.A., Hewitson, K.S., O'Rourke, J.,  
Mole, D.R., Mukherji, M., Metzen, E., Wilson, M.I., Dhanda, A., Tian, 
Y.M., Masson, N., Hamilton, D.L., Jaakkola, P., Barstead, R., Hodgkin, 
J., Maxwell, P.H., Pugh, C.W., Schofield, C.J., and Ratcliffe, P.J. 
(2001) C. elegans EGL-9 and mammalian homologs define a family of 
dioxygenases that regulate HIF by prolyl hydroxylation. Cell 107, 
43–54. 
Iliopoulos, O., Levy, A.P., Jiang, C., Kaelin, W.G., Jr., and Goldberg, M.A. 
(1996) Negative regulation of hypoxia-inducible genes by the von 
Hippel-Lindau protein. Proc Natl Acad Sci USA 93, 10595-10599. 
Ivan, M., Haberberger, T., Gervasi, D.C., Michelson, K.S., Günzler, V., 
Kondo, K., Yang, H., Sorokina, I., Conaway, R.C., Conaway, J.W., and 
Kaelin, W.G., Jr. (2002) Biochemical purification and pharmacological 
inhibition of a mammalian prolyl hydroxylase acting on hypoxia- 
inducible factor. Proc Natl Acad Sci USA 99, 13459–13464. 
Iyer, N.V., Kotch, L.E., Agani, F., Leung, S.W., Laughner, E., Wenger, 
R.H., Gassmann, M., Gearhart, J.D., Lawler, A.M., Yu, A.Y., and 
Semenza, G.L. (1998) Cellular and developmental control of O2 
homeostasis by hypoxia-inducible factor 1 alpha. Genes Dev 12, 
149–162. 
Lando, D., Peet, D.J., Gorman, J.J., Whelan, D.A., Whitelaw, M.L., and 
Bruick, R.K. (2002) FIH-1 is an asparaginyl hydroxylase enzyme that 
regulates the transcriptional activity of hypoxia-inducible factor. Genes 
Dev 16, 1466–1471. 
Maxwell, P.H., Wiesener, M.S., Chang, G.W., Clifford, S.C., Vaux, E.C., 
Cockman, M.E., Wykoff, C.C., Pugh, C.W., Maher, E.R., and Ratcliffe, 
P.J. (1999) The tumour suppressor protein VHL targets 
hypoxia-inducible factors for oxygen-dependent proteolysis. Nature 
399, 271–275. 
Wang, G.L., Jiang, B.H., Rue, E.A., and Semenza, G.L. (1995) 
Hypoxia-inducible factor 1 is a basic-helix-loop-helix-PAS heterodimer 
regulated by cellular O2 tension. Proc Natl Acad Sci USA 92, 
5510–5514.  
 
Open Access This article is distributed under the terms of the Creative Commons Attribution License which permits any use, distribution, and reproduction 
in any medium, provided the original author(s) and source are credited. 
